Pfizer Reports Revenue Decline Amid Shift to Obesity Drug Programs

Pfizer has announced a decline in revenue, primarily attributed to reduced sales of COVID-related products and a significant impairment charge of $4.4 billion. This financial setback comes as the company shifts its focus towards developing obesity drug programs and expanding its pipeline of pivotal clinical trials.

Despite the revenue drop, Pfizer's share price has shown resilience, with a 7.45% increase over the past 90 days and a 9.45% rise year-to-date. The company's total shareholder return over the past year stands at 33.52%, although this is contrasted by weaker returns over the previous three and five-year periods.

The strategic pivot towards obesity treatments indicates Pfizer's response to changing market dynamics and aims to capitalize on new growth opportunities in this therapeutic area. The company is expected to continue investing in its drug development pipeline as it navigates the evolving landscape of healthcare.

© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Source: KLEA News